Abl Bio Inc.

Yuhan Corporation

Yeunju Kim

Yangsoon Lee

Eunsil Sung

Byungje Sung

Hyejin Chung

Youngdon Pak

Jinhyung Ahn

Kyeongsu Park

Kyungjin Park

Juhee Kim

Eunyoung Park

Donghoon Yeom

Daehae Song

Jaehyun Eom

Jinwon Jung

Dongin Kim

Sang Hoon Lee

Bora Lee

Eun-Jung Lee

Yong-Gyu Son

Jiseon Yoo

Jaeho Jung

Ui-Jung Jung

Seawon Ahn

Uijung Jung

Sungwon An

Seung-Jae Lee

Tae Kyung Kim

Moo Young Song

Na Rae Lee

Minji Park

Eunjung Kim

Young Bong Park

Youngkwang Kim

Hyoju Choi

Yeryoung Yong

Wonjun Son

YoungKwang Kim

Jun Hyun Jeong

Mikyung Chang

Jaehyoung Jeon

Junhyun Jeong

Sang-Jun Ha

Myeong Joon Kim

Weonkyoo You

Min Sun Choi

Yoseob Lee

Yonggyu Son

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

Anti-alpha-synuclein antibodies and uses thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Growing community of inventors

Seongnam-si, South Korea

Yeunju Kim